IMPL Stock Price, Chart, Stats & News
Impel Pharmaceuticals Inc. (IMPL) does not currently pay a dividend.
IMPL chart
Fundamentals
Gross margin | 48.66% |
Operating margin | -657.48% |
Pretax margin | -840.28% |
Net margin | -1023.08% |
Effective tax rate | -21.75% |
ROA | -146.18% |
ROE | -3099.99% |
D/E | -1.16x |
Interest coverage ratio | -6.01x |
IMPL valuation
P/E | – |
P/S | 0.08x |
P/B | -0.02x |
P/CF | -0.01x |
P/FCF | -0.01x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | -0.11x |
About
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder.
Similar securities
Based on sector and market capitalization
